mafosfamide has been researched along with B16 Melanoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gambacorti-Passerini, C; Mariani, M; Parmiani, G; Radrizzani, M; Rivoltini, L; Supino, R | 1 |
1 review(s) available for mafosfamide and B16 Melanoma
| Article | Year |
|---|---|
Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2-activated lymphocytes (LAK).
Topics: Animals; Cell Survival; Cyclophosphamide; Cytotoxicity, Immunologic; Drug Resistance; Humans; Immunity, Cellular; Immunotherapy; Interleukin-2; Killer Cells, Natural; Melanoma, Experimental; Neoplasms; Recombinant Proteins; Tumor Cells, Cultured | 1988 |